Long COVID and Biomarker Dysregulation—A Shift Toward Immune Exhaustion?

<i>Background:</i> SARS-CoV-2 infection can lead to persistent or newly emerging symptoms lasting for months, a condition known as long COVID (LC). The pathophysiology of LC remains poorly understood, with cytokine dysregulation proposed as a key mechanism, although findings across the s...

Full description

Saved in:
Bibliographic Details
Main Authors: Anne Kallaste, Kalle Kisand, Agnes Aart, Ahto Salumets, Kai Kisand, Pärt Peterson, Margus Lember
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Medicina
Subjects:
Online Access:https://www.mdpi.com/1648-9144/61/6/996
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849431884635832320
author Anne Kallaste
Kalle Kisand
Agnes Aart
Ahto Salumets
Kai Kisand
Pärt Peterson
Margus Lember
author_facet Anne Kallaste
Kalle Kisand
Agnes Aart
Ahto Salumets
Kai Kisand
Pärt Peterson
Margus Lember
author_sort Anne Kallaste
collection DOAJ
description <i>Background:</i> SARS-CoV-2 infection can lead to persistent or newly emerging symptoms lasting for months, a condition known as long COVID (LC). The pathophysiology of LC remains poorly understood, with cytokine dysregulation proposed as a key mechanism, although findings across the studies have been inconsistent. <i>Patients and methods:</i> We conducted a longitudinal study using the Olink<sup>®</sup> Target 96 Inflammation Panel to assess cytokines in COVID-19 (COV) patients at three months and six months post-infection. These profiles were compared with those of individuals recovering from other upper respiratory tract infections (non-COV). Additionally, we analyzed differences between individuals with LC and those who recovered from COVID-19. Predictive models for LC at three months and sixth months post-infection were developed using inflammatory markers and relevant clinical cofactors, including gender, age, BMI, hemogram, Β2-microglobulin, D-dimers, LDH, AST, ALT, Ferritin, vitamin D, CRP, and the severity of acute COVID-19 infection as classified by WHO criteria. <i>Results:</i> We observed a general decline in inflammatory biomarkers in post-COVID-19 patients over time, with only a few cytokines elevated (CCL4 at month 3 and CST5 at month 6) compared to non-COV controls. In LC patients, an early phase of low-grade inflammation transitioned into significant reduction in proinflammatory biomarkers compared to recovered individuals. Rather than indicating immune normalization, this pattern suggests a possible suppression or exhaustion of the immune response in the months following acute infection. Importantly, our predictive modeling demonstrated that this specific cytokine signature, in combination with acute disease severity and clinical cofactors, described well the presence of LC. <i>Conclusions:</i> Our findings suggest that inflammation-related biomarker dysregulation following acute SARS-CoV-2 infection evolves dynamically over a six-month period. By the sixth month, compared to the third month, the presence of LC is more accurately predicted by a combination of persistent biomarker alteration and the severity of the initial infection, as defined by WHO criteria. This represents a novel insight, as previous studies have primarily associated LC with elevated proinflammatory markers, whereas our results suggest that immune suppression or exhaustion may play a more prominent role in the later stages.
format Article
id doaj-art-fcc0b4e5fd074bcea22efc470055d79b
institution Kabale University
issn 1010-660X
1648-9144
language English
publishDate 2025-05-01
publisher MDPI AG
record_format Article
series Medicina
spelling doaj-art-fcc0b4e5fd074bcea22efc470055d79b2025-08-20T03:27:29ZengMDPI AGMedicina1010-660X1648-91442025-05-0161699610.3390/medicina61060996Long COVID and Biomarker Dysregulation—A Shift Toward Immune Exhaustion?Anne Kallaste0Kalle Kisand1Agnes Aart2Ahto Salumets3Kai Kisand4Pärt Peterson5Margus Lember6Department of Internal Medicine, Tartu University Hospital, L. Puusepa 8, 51014 Tartu, EstoniaDepartment of Internal Medicine, Institute of Clinical Medicine, University of Tartu, L. Puusepa 8, 51014 Tartu, EstoniaSouth-Estonian Hospital, Meegomäe, 65526 Võru County, EstoniaFaculty of Science and Technology, Institute of Computer Science, University of Tartu, Narva mnt 18, 51009 Tartu, EstoniaMolecular Pathology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 19, 50411 Tartu, EstoniaMolecular Pathology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 19, 50411 Tartu, EstoniaDepartment of Internal Medicine, Tartu University Hospital, L. Puusepa 8, 51014 Tartu, Estonia<i>Background:</i> SARS-CoV-2 infection can lead to persistent or newly emerging symptoms lasting for months, a condition known as long COVID (LC). The pathophysiology of LC remains poorly understood, with cytokine dysregulation proposed as a key mechanism, although findings across the studies have been inconsistent. <i>Patients and methods:</i> We conducted a longitudinal study using the Olink<sup>®</sup> Target 96 Inflammation Panel to assess cytokines in COVID-19 (COV) patients at three months and six months post-infection. These profiles were compared with those of individuals recovering from other upper respiratory tract infections (non-COV). Additionally, we analyzed differences between individuals with LC and those who recovered from COVID-19. Predictive models for LC at three months and sixth months post-infection were developed using inflammatory markers and relevant clinical cofactors, including gender, age, BMI, hemogram, Β2-microglobulin, D-dimers, LDH, AST, ALT, Ferritin, vitamin D, CRP, and the severity of acute COVID-19 infection as classified by WHO criteria. <i>Results:</i> We observed a general decline in inflammatory biomarkers in post-COVID-19 patients over time, with only a few cytokines elevated (CCL4 at month 3 and CST5 at month 6) compared to non-COV controls. In LC patients, an early phase of low-grade inflammation transitioned into significant reduction in proinflammatory biomarkers compared to recovered individuals. Rather than indicating immune normalization, this pattern suggests a possible suppression or exhaustion of the immune response in the months following acute infection. Importantly, our predictive modeling demonstrated that this specific cytokine signature, in combination with acute disease severity and clinical cofactors, described well the presence of LC. <i>Conclusions:</i> Our findings suggest that inflammation-related biomarker dysregulation following acute SARS-CoV-2 infection evolves dynamically over a six-month period. By the sixth month, compared to the third month, the presence of LC is more accurately predicted by a combination of persistent biomarker alteration and the severity of the initial infection, as defined by WHO criteria. This represents a novel insight, as previous studies have primarily associated LC with elevated proinflammatory markers, whereas our results suggest that immune suppression or exhaustion may play a more prominent role in the later stages.https://www.mdpi.com/1648-9144/61/6/996post-COVID-19long COVIDSARS-CoV-2Olink proteomicsinflammation
spellingShingle Anne Kallaste
Kalle Kisand
Agnes Aart
Ahto Salumets
Kai Kisand
Pärt Peterson
Margus Lember
Long COVID and Biomarker Dysregulation—A Shift Toward Immune Exhaustion?
Medicina
post-COVID-19
long COVID
SARS-CoV-2
Olink proteomics
inflammation
title Long COVID and Biomarker Dysregulation—A Shift Toward Immune Exhaustion?
title_full Long COVID and Biomarker Dysregulation—A Shift Toward Immune Exhaustion?
title_fullStr Long COVID and Biomarker Dysregulation—A Shift Toward Immune Exhaustion?
title_full_unstemmed Long COVID and Biomarker Dysregulation—A Shift Toward Immune Exhaustion?
title_short Long COVID and Biomarker Dysregulation—A Shift Toward Immune Exhaustion?
title_sort long covid and biomarker dysregulation a shift toward immune exhaustion
topic post-COVID-19
long COVID
SARS-CoV-2
Olink proteomics
inflammation
url https://www.mdpi.com/1648-9144/61/6/996
work_keys_str_mv AT annekallaste longcovidandbiomarkerdysregulationashifttowardimmuneexhaustion
AT kallekisand longcovidandbiomarkerdysregulationashifttowardimmuneexhaustion
AT agnesaart longcovidandbiomarkerdysregulationashifttowardimmuneexhaustion
AT ahtosalumets longcovidandbiomarkerdysregulationashifttowardimmuneexhaustion
AT kaikisand longcovidandbiomarkerdysregulationashifttowardimmuneexhaustion
AT partpeterson longcovidandbiomarkerdysregulationashifttowardimmuneexhaustion
AT marguslember longcovidandbiomarkerdysregulationashifttowardimmuneexhaustion